SPRY2 and hepatocellular carcinoma: For example, miR-330-5p accelerates the progression of HCC by targeting SPRY2 to activate MAPK/ERK signaling (25); miR-185-5p targets ROCK2 and restrains migration and invasion of HCC cells (26).